Reasons for and Outcomes of Medicare Part D Appeals for Denied GLP-1 Receptor Agonist Claims [0.03%]
关于医保部分D计划中拒绝GLP-1受体激动剂索赔的上诉原因及结果分析
Matthew J Klebanoff,John C Lin,Judith A Long et al.
Matthew J Klebanoff et al.
Devika Umashanker,James Mitchell
Devika Umashanker
Prescribed but Not Filled: Patient Factors Related to Semaglutide/Tirzepatide Prescription Fills Among Those With Prescription Orders for Obesity Treatment [0.03%]
被开药但未取药：肥胖患者中司美格鲁肽/ tirzepatide处方获取的相关因素分析
Mahip Acharya,Deboleena Thakur
Mahip Acharya
Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated and GRADE Assessed Systematic Review and Meta-Analysis of Randomised Controlled Trials [0.03%]
成人高胆固醇血症口服PCSK9抑制剂疗效和安全性的系统评价和meta分析（附GRADE证据评级）
Muhammad Huzaifa Khattak,Sohana Memon,Humaira Bibi et al.
Muhammad Huzaifa Khattak et al.
Purpose: To evaluate the efficacy and safety of oral PCSK9 inhibitors in adults with hypercholesterolemia by synthesizing evidence from randomised controlled trials. ...
Feasibility and Effects of a Produce Prescription Program (PRx) in People With Type 2 Diabetes and Low Socioeconomic Status: A Randomised Controlled Pilot Trial [0.03%]
针对低社会经济状态的2型糖尿病患者的食品处方项目（PRx）的可行性和影响：随机对照试点试验
Carmen A W Dietvorst,Zuzanna Zielinska,Raief Ahmadkhan et al.
Carmen A W Dietvorst et al.
Aims: Financial constraints often limit healthy eating among individuals with Type 2 diabetes (T2D) and lower socioeconomic status (SES). Produce Prescription Programs (PRx), which provide financial support for healthy fo...
AI Patient Support and 6-Month Medication Adherence in a Digital Obesity Program: A Retrospective Analysis [0.03%]
人工智能患者支持和数字肥胖计划中的6个月药物依从性：回顾性分析
Louis Talay,Connie Xu,John Alderete et al.
Louis Talay et al.
Background: Real-world glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapies face substantial attrition rates in commercial digital weight loss services (DWLSs). Conversational artificial intelligence (AI) has bee...
Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6-Month Claims Database Analysis [0.03%]
司美格鲁肽在美国超重或肥胖成人中的用药依从性及其对临床转归的影响：为期6个月的理赔数据库分析
Theresa Hunter Gibble,Malvika Venkataraman,Donna Mojdami et al.
Theresa Hunter Gibble et al.
Aims: Tirzepatide is a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the US for the treatment of Type 2 diabetes (T2D), weight loss and obstru...
Systematic Comparison of High-Fat Diet- and Streptozotocin-Induced Prediabetic Obese C57BL/6J Mouse Models: A Sex-Based Protocol Optimization Study [0.03%]
基于性别优化的系统比较高脂饮食和链脲佐菌素诱导的C57BL/6J小鼠前驱糖尿病肥胖模型的研究
Min Xu,Chao Ke,Yangkun Liu et al.
Min Xu et al.
Aims: Animal models of prediabetes (Pre-DM) are essential for studying metabolic disease and testing therapies, yet high-fat diet (HFD) and HFD-plus-streptozotocin (STZ) protocols vary in feeding duration, STZ dose, and d...
Economic Burden of Overweight and Obesity in Sweden: Current Estimates and Future Projections [0.03%]
瑞典肥胖和体重超标带来的经济负担：当前估算与未来预测
Adam Fridhammar,Jovanna Dahlgren,Marije Galavazi et al.
Adam Fridhammar et al.
Aims: Overweight and obesity are major public health challenges and well-established risk factors for cardiovascular disease, cancer and premature mortality. We estimated the economic burden of overweight and obesity in S...
Economic Burden of Overweight and Obesity in Sweden: Current Estimates and Future Projections [0.03%]
瑞典肥胖和体重超标经济负担的估算及未来预测
Adam Fridhammar,Jovanna Dahlgren,Marije Galavazi et al.
Adam Fridhammar et al.
Aims: Overweight and obesity are major public health challenges and well-established risk factors for cardiovascular disease, cancer and premature mortality. We estimated the economic burden of overweight and obesity in S...